{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:29:40Z","timestamp":1793672980405,"version":"4.5.1"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004083","name":"Ministry of Science ICT and Future Planning","doi-asserted-by":"publisher","award":["NRF-2013R1A1A2012193"],"award-info":[{"award-number":["NRF-2013R1A1A2012193"]}],"id":[{"id":"10.13039\/501100004083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004083","name":"Ministry of Science ICT and Future Planning","doi-asserted-by":"publisher","award":["NRF-2016R1D1A1B01015369"],"award-info":[{"award-number":["NRF-2016R1D1A1B01015369"]}],"id":[{"id":"10.13039\/501100004083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["NRF-2016R1A6A1A03011325"],"award-info":[{"award-number":["NRF-2016R1A6A1A03011325"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jconrel.2021.08.060","type":"journal-article","created":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T11:19:10Z","timestamp":1630581550000},"page":"644-661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Bile acid transporter-mediated oral absorption of insulin via hydrophobic ion-pairing approach"],"prefix":"10.1016","volume":"338","author":[{"given":"Santosh","family":"Bashyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo-Eun","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Wook","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangkil","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2021.08.060_bb0005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.addr.2016.02.004","article-title":"Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials","volume":"106","author":"Aguirre","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0010","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0015","first-page":"1","article-title":"Advances in oral peptide therapeutics","author":"Drucker","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0020","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1039\/C7CS00877E","article-title":"Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications","volume":"47","author":"Spicer","year":"2018","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40005-016-0253-0","article-title":"Cell penetrating peptides as an innovative approach for drug delivery; then, present and the future","volume":"46","author":"Bashyal","year":"2016","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0030","first-page":"1","article-title":"Materials for oral delivery of proteins and peptides","author":"Brown","year":"2019","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0035","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.addr.2016.06.005","article-title":"Intestinal permeation enhancers for oral peptide delivery","volume":"106","author":"Maher","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0040","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0169-409X(92)90015-I","article-title":"(C) Means to enhance penetration:(2) Intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity","volume":"8","author":"Swenson","year":"1992","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0045","doi-asserted-by":"crossref","first-page":"73986","DOI":"10.1039\/C6RA10978K","article-title":"Design and strategies for bile acid mediated therapy and imaging","volume":"6","author":"Nurunnabi","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0050","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijpharm.2013.04.003","article-title":"Bile salts and their importance for drug absorption","volume":"453","author":"Holm","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0055","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3389\/fphar.2018.01283","article-title":"Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles","volume":"9","author":"Pavlovi\u0107","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0060","first-page":"1155","article-title":"Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation","volume":"6","author":"Niu","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0065","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.4314\/tjpr.v13i11.4","article-title":"Enhancing effect of bile salts on gastrointestinal absorption of insulin","volume":"13","author":"Jalali","year":"2014","journal-title":"Trop. J. Pharm. Res."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0070","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.xphs.2017.12.012","article-title":"Bile acid as an effective absorption enhancer for oral delivery of epidermal growth factor receptor\u2013targeted hybrid peptide","volume":"107","author":"Gaowa","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0075","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jconrel.2020.04.006","article-title":"Overcoming the intestinal barrier: a look into targeting approaches for improved oral drug delivery systems","volume":"322","author":"Xu","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0080","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J","article-title":"Intestinal permeation enhancers","volume":"89","author":"Aungst","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0085","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1515\/bc.2011.017","article-title":"Transporters, Trojan horses and therapeutics: suitability of bile acid and peptide transporters for drug delivery","volume":"392","author":"Kramer","year":"2011","journal-title":"Biol. Chem."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0090","series-title":"Drug Transporters. Handbook of Experimental Pharmacology","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-3-642-14541-4_4","article-title":"Role of the intestinal bile acid transporters in bile acid and drug disposition, in: K.R","author":"Dawson","year":"2011"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0095","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1073\/pnas.80.8.2258","article-title":"pH and the recycling of transferrin during receptor-mediated endocytosis","volume":"80","author":"Dautry-Varsat","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0100","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1023\/A:1011908128045","article-title":"Recent advances in intestinal macromolecular drug delivery via receptor-mediated transport pathways","volume":"15","author":"Swaan","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0105","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s11095-007-9289-1","article-title":"Bile acid transporters: structure, function, regulation and pathophysiological implications","volume":"24","author":"Alrefai","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0110","doi-asserted-by":"crossref","first-page":"42283","DOI":"10.1074\/jbc.M507454200","article-title":"Ileal bile acid-binding protein, functionally associated with the farnesoid X receptor or the ileal bile acid transporter, regulates bile acid activity in the small intestine","volume":"280","author":"Nakahara","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.biomaterials.2017.10.022","article-title":"Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery","volume":"151","author":"Fan","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.biomaterials.2017.09.022","article-title":"Bile acid transporter mediated endocytosis of oral bile acid conjugated nanocomplex","volume":"147","author":"Park","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0125","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1038\/srep04163","article-title":"Functional transformations of bile acid transporters induced by high-affinity macromolecules","volume":"4","author":"Al-Hilal","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0130","doi-asserted-by":"crossref","first-page":"8893","DOI":"10.1021\/acsnano.8b04315","article-title":"Oral nanoparticles exhibit specific high-efficiency intestinal uptake and lymphatic transport","volume":"12","author":"Kim","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0135","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1021\/acs.molpharmaceut.9b00827","article-title":"Flash fabrication of orally targeted Nanocomplexes for improved transport of Salmon calcitonin across the intestine","volume":"17","author":"Sun","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0140","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1021\/mp500626a","article-title":"Absorption mechanism of a physical complex of monomeric insulin and deoxycholyl-l-lysyl-methylester in the small intestine","volume":"12","author":"Mahmud","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0145","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.xphs.2019.01.027","article-title":"A delivery system for oral administration of proteins\/peptides through bile acid transport channels","volume":"108","author":"Wu","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0150","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.biomaterials.2015.03.048","article-title":"Deoxycholate bile acid directed synthesis of branched au nanostructures for near infrared photothermal ablation","volume":"56","author":"Kim","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0155","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1023\/A:1011998014474","article-title":"Hydrophobic ion pairing: altering the solubility properties of biomolecules","volume":"15","author":"Meyer","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0160","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrd2619","article-title":"Targeting bile-acid signalling for metabolic diseases","volume":"7","author":"Thomas","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0165","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1039\/C9NA00308H","article-title":"Hydrophobic ion pairing: encapsulating small molecules, peptides, and proteins into nanocarriers","volume":"1","author":"Ristroph","year":"2019","journal-title":"Nanoscale Adv."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0170","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.4155\/tde.11.128","article-title":"Opportunities and challenges for oral delivery of hydrophobic versus hydrophilic peptide and protein-like drugs using lipid-based technologies","volume":"2","author":"Griffin","year":"2011","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0175","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.addr.2016.04.001","article-title":"Lipid-based nanocarriers for oral peptide delivery","volume":"106","author":"Niu","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0180","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jconrel.2019.05.011","article-title":"Hydrophobic ion-pairs and lipid-based nanocarrier systems: the perfect match for delivery of BCS class 3 drugs","volume":"304","author":"Phan","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0185","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2012.06.002","article-title":"Improvement of drug safety by the use of lipid-based nanocarriers","volume":"163","author":"Lim","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0190","author":"Labrasol\u00ae"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0195","series-title":"Handbook of Pharmaceutical Excipients","author":"Rowe","year":"2009"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0200","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1002\/adfm.201505252","article-title":"Thiolation and cell-penetrating peptide surface functionalization of porous silicon nanoparticles for oral delivery of insulin","volume":"26","author":"Shrestha","year":"2016","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0205","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.2147\/IJN.S168310","article-title":"Facilitated permeation of insulin across TR146 cells by cholic acid derivatives-modified elastic bilosomes","volume":"13","author":"Bashyal","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0210","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/nprot.2007.303","article-title":"Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers","volume":"2","author":"Hubatsch","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0215","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s11095-012-0932-0","article-title":"Oral delivery of ionic complex of ceftriaxone with bile acid derivative in non-human primates","volume":"30","author":"Jeon","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0220","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.2147\/IJN.S167958","article-title":"Enhanced oral absorption of pemetrexed by ion-pairing complex formation with deoxycholic acid derivative and multiple nanoemulsion formulations: preparation, characterization, and in vivo oral bioavailability and anticancer effect","volume":"13","author":"Pangeni","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0225","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF01960074","article-title":"Ion pair absorption of ionized drugs\u2014fact or fiction?","volume":"5","author":"Jonkman","year":"1983","journal-title":"Pharm. Weekbl. Sci."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0230","doi-asserted-by":"crossref","first-page":"14451","DOI":"10.3390\/molecules200814451","article-title":"Absorption-enhancing effects of bile salts","volume":"20","author":"Moghimipour","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0235","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3748\/wjg.15.804","article-title":"Bile acids: chemistry, physiology, and pathophysiology","volume":"15","author":"Monte","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0240","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jconrel.2017.04.038","article-title":"Lipophilic peptide character\u2013what oral barriers fear the most","volume":"255","author":"Zupan\u010di\u010d","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0245","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijpharm.2009.01.022","article-title":"Evaluation of pharmacological efficacy of \u2018insulin\u2013surfoplex\u2019encapsulated polymer vesicles","volume":"373","author":"Rastogi","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0250","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1021\/jf981370y","article-title":"Interaction of alkylsulfonate ligands with \u03b2-lactoglobulin AB from bovine milk","volume":"47","author":"Busti","year":"1999","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0255","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1021\/ja00057a006","article-title":"Structure and stability of insulin dissolved in 1-octanol","volume":"115","author":"Matsuura","year":"1993","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0260","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.bbapap.2011.03.003","article-title":"Protein\u2013surfactant interactions: a tale of many states","volume":"1814","author":"Otzen","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0265","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jcis.2018.07.057","article-title":"Trypsin decorated self-emulsifying drug delivery systems (SEDDS): key to enhanced mucus permeation","volume":"531","author":"Shahzadi","year":"2018","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0270","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ijpharm.2017.02.019","article-title":"Hydrophobic ion pairing: key to highly payloaded self-emulsifying peptide drug delivery systems","volume":"520","author":"Griesser","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0275","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3109\/02652040903515490","article-title":"Insulin-SO (sodium oleate) complex-loaded PLGA nanoparticles: formulation, characterization and in vivo evaluation","volume":"27","author":"Sun","year":"2010","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0280","first-page":"3049","article-title":"Hydrophobic ion pairing of an insulin-sodium deoxycholate complex for oral delivery of insulin","volume":"6","author":"Sun","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0285","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jconrel.2019.08.036","article-title":"Development of pH-responsive organic-inorganic hybrid nanocomposites as an effective oral delivery system of protein drugs","volume":"311","author":"Lee","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0290","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s11095-009-0045-6","article-title":"Stability of protein pharmaceuticals: an update","volume":"27","author":"Manning","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0295","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1021\/bc049871e","article-title":"Synthesis and biological properties of insulin\u2212 Deoxycholic acid chemical conjugates","volume":"16","author":"Lee","year":"2005","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0300","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijpharm.2006.11.035","article-title":"Characterization of physiochemical and biological properties of an insulin\/lauryl sulfate complex formed by hydrophobic ion pairing","volume":"336","author":"Dai","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0305","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijpharm.2019.03.001","article-title":"Self-emulsifying drug delivery systems: impact of stability of hydrophobic ion pairs on drug release","volume":"561","author":"Nazir","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0310","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0378-5173(86)90153-5","article-title":"Bile salts and intranasal drug absorption","volume":"31","author":"Duchateau","year":"1986","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0315","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.tiv.2012.11.018","article-title":"Lecithin in mixed micelles attenuates the cytotoxicity of bile salts in Caco-2 cells","volume":"27","author":"Tan","year":"2013","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0320","doi-asserted-by":"crossref","first-page":"7419","DOI":"10.1073\/pnas.82.21.7419","article-title":"Nasal absorption of insulin: enhancement by hydrophobic bile salts","volume":"82","author":"Gordon","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10565-005-0085-6","article-title":"The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics","volume":"21","author":"Sambuy","year":"2005","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0330","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.2147\/IJN.S209722","article-title":"Intestinal transport mechanism and in vivo anticancer efficacy of a solid oral formulation incorporating an ion-pairing complex of pemetrexed with deoxycholic acid derivative","volume":"14","author":"Pangeni","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0335","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijpharm.2013.07.066","article-title":"Enhanced bioavailability of poorly absorbed hydrophilic compounds through drug complex\/in situ gelling formulation","volume":"457","author":"Dai","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0340","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jconrel.2005.05.016","article-title":"Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts","volume":"106","author":"Song","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0345","series-title":"In Vitro Models in Drug Discovery and Delivery","author":"Mitra","year":"2014"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0350","doi-asserted-by":"crossref","first-page":"E28","DOI":"10.1208\/pt0803055","article-title":"Transbuccal delivery of 5-Aza-2\u2032-deoxycytidine: effects of drug concentration, buffer solution, and bile salts on permeation","volume":"8","author":"Mahalingam","year":"2007","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0355","first-page":"134","article-title":"Synthetic bile acids: novel mediators of apoptosis","volume":"35","author":"Kim","year":"2002","journal-title":"J. Biochem. Mol. Biol."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0360","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1021\/mp400493b","article-title":"Penetratin derivative-based nanocomplexes for enhanced intestinal insulin delivery","volume":"11","author":"Zhu","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0365","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1600-0854.2007.00572.x","article-title":"A comprehensive model for the cellular uptake of cationic cell-penetrating peptides","volume":"8","author":"Duchardt","year":"2007","journal-title":"Traffic."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0370","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1021\/mp060022d","article-title":"Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target","volume":"3","author":"Balakrishnan","year":"2006","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0375","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s11095-005-5274-8","article-title":"Development of stably transfected monolayer overexpressing the human apical sodium-dependent bile acid transporter (hASBT)","volume":"22","author":"Balakrishnan","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0380","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s11095-006-0219-4","article-title":"Interaction of native bile acids with human apical sodium-dependent bile acid transporter (hASBT): influence of steroidal hydroxylation pattern and C-24 conjugation","volume":"23","author":"Balakrishnan","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0385","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2013.12.001","article-title":"Oligomeric bile acid-mediated oral delivery of low molecular weight heparin","volume":"175","author":"Al-Hilal","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0390","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jconrel.2019.08.008","article-title":"Labrasol\u00ae is an efficacious intestinal permeation enhancer across rat intestine: ex vivo and in vivo rat studies","volume":"310","author":"McCartney","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.08.060_bb0395","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/10611860290022688","article-title":"Absorption enhancing effect of labrasol on the intestinal absorption of insulin in rats","volume":"10","author":"Eaimtrakarn","year":"2002","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2021.08.060_bb0400","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1194\/jlr.R054114","article-title":"Intestinal transport and metabolism of bile acids","volume":"56","author":"Dawson","year":"2015","journal-title":"J. Lipid Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921004740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921004740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:16:27Z","timestamp":1759162587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365921004740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":80,"alternative-id":["S0168365921004740"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.08.060","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bile acid transporter-mediated oral absorption of insulin via hydrophobic ion-pairing approach","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.08.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}